Sequenta and Collaborators to Share ClonoSIGHT MRD Data in Four Presentations at EHA
SOUTH SAN FRANCISCO, Calif. MAY 22, 2014 – Sequenta, Inc. and its academic collaborators will share data about the use of the company’s next-generation sequencing-based assay for minimal residual disease (MRD) in lymphoid cancers (available clinically in the United States as the ClonoSIGHT™ test) in one oral and three poster presentations at the 19th Congress […]